The reputational dividends of collaborating with a highly reputable agency: The case of interagency collaboration between the U.S. FDA and its domestic partner agencies

Moshe Maor*, Raanan Sulitzeanu-Kenan, Meital Balmas

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

What reputational dividends in the media, if any, do federal agencies reap from collaboration with a highly reputable agency, such as the U.S. Food and Drug Administration (FDA)? Utilizing a dataset covering 30 U.S. federal agencies over a period of 34 years (1980–2013), we estimate the short and long-term reputational effects of interagency collaboration. Collaboration is measured by the number of memorandums of understanding in effect between each agency and the FDA, while agency reputation in the media is assessed using an automated measure of media-coverage valence (positive/negative tone) for each agency-year. To account for potential reverse and reciprocal causality, we utilize cross-lagged fixed-effects models. We find evidence of moderate rises in reputation in the media due to increased collaboration with the FDA. These effects persist significantly for 2 years following the end of the collaboration, before declining to null after 4 years. Employing similar analyses, we furthermore estimate reverse causality—of reputation in the media on the level of consequent collaboration—finding no evidence of such effects.

Original languageAmerican English
Pages (from-to)639-653
Number of pages15
JournalPublic Administration Review
Volume83
Issue number3
DOIs
StatePublished - 2023

Bibliographical note

Funding Information:
Moshe Maor and Raanan Sulitzeanu‐Kenan acknowledge funding from the Israel Science Foundation, Grant 1002/11.

Publisher Copyright:
© 2023 The Authors. Public Administration Review published by Wiley Periodicals LLC on behalf of American Society for Public Administration.

Fingerprint

Dive into the research topics of 'The reputational dividends of collaborating with a highly reputable agency: The case of interagency collaboration between the U.S. FDA and its domestic partner agencies'. Together they form a unique fingerprint.

Cite this